The total amount payable to entity for the achievement of regulatory and commercial milestones.

No definition available.

Name:	plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount payable to the entity to cover development costs under agreement.

+ References

No definition available.

+ Details

Name:	plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative arrangement profit sharing percentage.

+ References

No definition available.

+ Details

Name:	plx_CollaborativeArrangementProfitSharePercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The maximum amount payable to entity to cover development costs in any year under agreement.

+ References

No definition available.

+ Details

Name:	plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of non refundable payment received for future service.

+ References

No definition available.

+ Details

Name:	plx_NonRefundableFutureServicePayment
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from consideration received for development services performed.

+ References

No definition available.

+ Details

Name:	plx_PaymentInConsiderationForDevelopmentServicesPerformed
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the payment as a percentage of future net sales.

+ References

No definition available.

+ Details

Name:	plx_PaymentOnNetSalesPercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow in connection with performance of additional studies.

+ References

No definition available.

+ Details

Name:	plx_PaymentsInConnectionWithPerformanceOfAdditionalStudies
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of adult Gaucher patients treated with Uplyso.

+ References

No definition available.

+ Details

Name:	plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.

+ References

No definition available.

+ Details

Name:	plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_NotesPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name:	us-gaap_ProceedsFromRepaymentsOfNotesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_StatementGeographicalAxis=country_BR
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_KirinHoldingsCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMERCIALIZATION AGREEMENTS (Details) - USD ($)		1 Months Ended			12 Months Ended
COMMERCIALIZATION AGREEMENTS (Details) - USD ($)	Mar. 16, 2020	Sep. 30, 2020	Jul. 23, 2018	Oct. 19, 2017	Dec. 31, 2020	Dec. 31, 2019	Oct. 31, 2015	Nov. 30, 2009
Promissory note					$ 4,086,000	$ 4,301,000
Brazil [Member]
Percentage Of Adult Gaucher Patients Treated With alfataliglicerase					25.00%
Pfizer [Member]
Collaborative Arrangement Profit Share Percentage								40.00%
Debt Instrument, Face Amount							$ 4,300,000
Promissory note		$ 4,300,000
Payment on notes payable		$ 430,000
Chiesi US Agreement and Chiesi Ex US Agreement [Member]
Upfront Nonrefundable Non-Creditable Payment Receivable				$ 25,000,000.0	$ 50,000,000.0
Payments in consideration for development services performed					45,000,000.0
Payments in connection with performance of additional studies					21,100,000
Recognized revenues related to non-refundable payment					3,500,000	4,500,000
Future milestone payment					10,000,000.0	$ 10,000,000.0
Chiesi US Agreement [Member]
Upfront Nonrefundable Non-Creditable Payment Receivable			$ 25,000,000.0	25,000,000.0
Additional Amounts Payable To Cover Development Costs			20,000,000.0
Maximum Entitlement Of Development Costs To Cover Per Year			7,500,000
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones			$ 760,000,000.0		$ 760,000,000.0
Chiesi US Agreement [Member] \| Maximum [Member]
Payment On Net Sales Percentage			40.00%		40.00%
Chiesi US Agreement [Member] \| Minimum [Member]
Payment On Net Sales Percentage			15.00%		15.00%
Chiesi Ex US Agreement [Member]
Upfront Nonrefundable Non-Creditable Payment Receivable				25,000,000.0
Additional Amounts Payable To Cover Development Costs				25,000,000.0
Maximum Entitlement Of Development Costs To Cover Per Year				10,000,000.0
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones				$ 320,000,000.0	$ 320,000,000.0
Chiesi Ex US Agreement [Member] \| Maximum [Member]
Payment On Net Sales Percentage				35.00%	35.00%
Chiesi Ex US Agreement [Member] \| Minimum [Member]
Payment On Net Sales Percentage				15.00%	15.00%
Kirin Holdings Company, Limited [Member]
Non-Refundable Future Service Payment	$ 1,000,000.0